NCT05714891

Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer

Neoadjuvant Platform Trial in Patients With Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: Canadian Cancer Trials Group · Network
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is being done to answer the following question: What are the effects of new treatments on non-small cell lung cancer before surgery?

Detailed description

The purpose of the pre-study screening is to test for biomarkers. The testing will be done using a sample of your tumor tissue. Each substudy will be looking at what effects a new drug has on the patients and their lung cancer, as well as any side effects of the treatment. The purpose of each substudy is to see if the biomarkers that were identified at screening can be used to determine treatment outcomes, like how the cancer cells respond to treatment and whether the study drug will shrink the tumour before surgery and prevent it from returning after surgery.

Conditions

• NSCLC

Interventions

Type	Name	Description
DRUG	JDQ443	Dose will be assigned at enrollment

Timeline

• Start date: 2023-09-15
• Primary completion: 2026-08-31
• Completion: 2028-03-31
• First posted: 2023-02-06
• Last updated: 2026-02-12

Locations

8 sites across 1 country: Canada